Related Experiment Video
Updated: May 11, 2026
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Selective internal radiotherapy and chemosaturation show equivalent survival in metastatic uveal melanoma: a
Elias A T Koch1,2,3,4, Louisa A Schielein5, Markus Reitmajer6
1Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, 91054, Germany.
Background:
Metastatic uveal melanoma (UM) primarily affects the liver, and due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for hepatic tumor control. Direct head-to-head trials comparing these LDTs are still lacking.
Methods:
A retrospective multicenter explorative analysis was conducted to evaluate the clinical outcomes of transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT), and percutaneous hepatic perfusion (PHP, chemosaturation).
Results:
The present analysis was conducted on a cohort of 121 patients who had been treated for metastatic UM with LDT at five different skin cancer centers. A total of n = 15 patients received TACE (12.4%), n = 51 SIRT (42.1%), and n = 55 PHP (45.5%). The estimated median overall survival (OS) for SIRT was 25.1 months (95% confidence interval [CI], 15.3-34.8), for TACE, 11.4 months (95% CI, 7.8-14.9), and for PHP, 24.9 months (95% CI, 13.7-36.0). In the multivariate analysis that included LDH and additional systemic therapies, there was no significant difference in OS between SIRT and PHP (HR 1.14, 95% CI 0.67-1.93, P = .63), whereas TACE was found to be associated with a substantially reduced in OS compared to PHP (HR 3.25, 95% CI 1.31-8.04, P = .01). Adverse events occurred in 41.6% of patients undergoing SIRT, 64.3% of patients receiving TACE, and 84.6% of patients receiving PHP.
Conclusion:
The findings of this study indicate that SIRT and PHP demonstrate equivalent survival rates in a real-world setting.
